Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan W Friedberg

Showing results (191-200 of 300) with videos related to

Pageof 30
Sort By:
British Journal of Haematology|October 23, 2015
Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601Brian G Till, Hongli Li, Steven H Bernstein, et al.
Cancer|October 19, 2011
Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national databaseAnita Kumar, Ann Vanderplas, Ann S LaCasce, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2022
The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC ConsortiumAngie Mae Rodday, Susan K Parsons, Jenica N Upshaw, et al.
Blood|January 18, 2011
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphomaJonathan W Friedberg, Julie M Vose, Jennifer L Kelly, et al.
Journal of the National Cancer Institute|January 2, 2017
Recommendations for Clinical Trial Development in Mantle Cell LymphomaStephen E Spurgeon, Brian G Till, Peter Martin, et al.
Journal of Geriatric Oncology|October 23, 2021
SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty toolElizabeth A Brem, Hongli Li, Anne W Beaven, et al.
JAMA Cardiology|March 29, 2023
Association of Preexisting Heart Failure With Outcomes in Older Patients With Diffuse Large B-Cell LymphomaJenica N Upshaw, Jason Nelson, Angie Mae Rodday, et al.
American Journal of Hematology|June 2, 2011
Intra-arterial methylprednisolone for the management of steroid-refractory acute gastrointestinal and hepatic graft versus host diseaseLaurie A Milner, Michael W Becker, Steven H Bernstein, et al.
Blood Advances|October 25, 2019
Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphomaManali Kamdar, Hongli Li, Robert W Chen, et al.
British Journal of Haematology|April 14, 2016
Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704Soham D Puvvada, Patrick J Stiff, Michael Leblanc, et al.
Pageof 30

Showing results (191-200 of 300) with videos related to

Sort By:
Pageof 30
British Journal of Haematology|October 23, 2015
Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601Brian G Till, Hongli Li, Steven H Bernstein, et al.
Cancer|October 19, 2011
Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national databaseAnita Kumar, Ann Vanderplas, Ann S LaCasce, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2022
The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC ConsortiumAngie Mae Rodday, Susan K Parsons, Jenica N Upshaw, et al.
Blood|January 18, 2011
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphomaJonathan W Friedberg, Julie M Vose, Jennifer L Kelly, et al.
Journal of the National Cancer Institute|January 2, 2017
Recommendations for Clinical Trial Development in Mantle Cell LymphomaStephen E Spurgeon, Brian G Till, Peter Martin, et al.
Journal of Geriatric Oncology|October 23, 2021
SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty toolElizabeth A Brem, Hongli Li, Anne W Beaven, et al.
JAMA Cardiology|March 29, 2023
Association of Preexisting Heart Failure With Outcomes in Older Patients With Diffuse Large B-Cell LymphomaJenica N Upshaw, Jason Nelson, Angie Mae Rodday, et al.
American Journal of Hematology|June 2, 2011
Intra-arterial methylprednisolone for the management of steroid-refractory acute gastrointestinal and hepatic graft versus host diseaseLaurie A Milner, Michael W Becker, Steven H Bernstein, et al.
Blood Advances|October 25, 2019
Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphomaManali Kamdar, Hongli Li, Robert W Chen, et al.
British Journal of Haematology|April 14, 2016
Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704Soham D Puvvada, Patrick J Stiff, Michael Leblanc, et al.
Pageof 30